[1]滕菲 南景龙.肺动脉高压的非药物治疗[J].心血管病学进展,2024,(1):31.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.009]
　TENG Fei,NAN Jinglong.Non-Drug reatment of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2024,(1):31.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.009]
点击复制

肺动脉高压的非药物治疗()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年1期
页码:
31
栏目:
主题综述
出版日期:
2024-02-21

文章信息/Info

Title:
Non-Drug reatment of Pulmonary Hypertension
作者:
滕菲 南景龙
(内蒙古自治区人民医院心内科,内蒙古 呼和浩特 010000)
Author(s):
TENG Fei; NAN Jinglong
(Department of Cardiology,Inner Mongolia Peoples Hospital,Hohhot 010000,Inner Mongolia,China)
关键词:
肺动脉高压; 非药物治疗; 临床治疗
Keywords:
Pulmonary hypertension; Non-drug treatment; Clinical treatment
DOI:
10.16806/j.cnki.issn.1004-3934.2024.01.009
摘要:
肺动脉高压（PH）是以肺动脉血流动力学异常为特征的一组临床综合征。其发病机制涉及多学科、系统和通路，治疗亦是多方面、多角度的。目前PH的治疗以药物治疗和非药物治疗为主。PH药物治疗的重点是动脉型PH和慢性血栓栓塞性PH，随着靶向药物（如内皮素受体抑制剂、前列环素类、磷酸二酯酶Ⅴ型抑制剂和可溶性鸟苷酸环化酶激动剂）的进展，患者预后有所改善，但5年生存率仍不超过70%。因此，可将非药物治疗方式作为PH治疗的另一选择。现就PH的非药物治疗做一综述。
Abstract:
Pulmonary hypertension(PH) is a group of clinical syndromes characterized by abnormal pulmonary hemodynamics. Its pathogenesis involves multiple disciplines,multiple systems and multiple pathways so that its treatment is multi-faceted and multi-angle. At present,the treatment of PH mainly involves drug treatment and non-drug treatment. The focus of drug treatment of PH are pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension. Even if the prognosis of PH patients is significantly improved by using targeted drugs such as endothelin receptor inhibitor,prostaglandin,phosphodiesterase type 5 inhibitor and soluble guanoylate cyclase agonist,the 5-year survival rate is still not more than 70%. Therefore,non-drug treatment can be used as another option for PH treatment. This article reviews the non-drug treatment of PH.

参考文献/References:

[1] 医学名词审定委员会编. 医学名词1995[M]. 北京:科学出版社,1996.
[2] 中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组,等. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志,2021,101(1):11-51.
[3] 国家心血管病中心肺动脉高压专科联盟,国家心血管病专家委员会右心与肺血管病专业委员会. 中国肺动脉高压诊治临床路径[J]. 中国循环杂志,2023,38(7):691-703.
[4] 葛均波,徐永健,王辰,等. 内科学[M]. 北京:人民卫生出版社,2018:105-108.
[5] Khan MS,Memon MM,Amin E,et al. Use of balloon atrial septostomy in patients with advanced pulmonary arterial hypertension:a systematic review and meta-analysis[J]. Chest,2019,156(1):53-63.
[6] D’Armini AM,Callegari G,Vitulo P,et al. Risk factors for early death in patients awaiting heart-lung or lung transplantation:experience at a single European center[J]. Transplantation,1998,66(1):123-127.
[7] Galiè N,Humbert M,Vachiery JL,et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension:The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC) and the European Respiratory Society(ERS):Endorsed by:Association for European Paediatric and Congenital Cardiology(AEPC),International Society for Heart and Lung Transplantation(ISHLT)[J]. Eur Heart J,2016,37(1):67-119.
[8] 尚小珂,张长东,陈澍,等. D-Shant心房分流器的初步动物实验研究[J]. 中国介入心脏病学杂志,2020,28(6):337-342.
[9] 肖书娜,尚小珂,张长东,等. 房间隔分流器在重度肺动脉高压患者中的应用[J]. 中国胸心血管外科临床杂志,2022,29(11):1525-1531.
[10] Rosenzweig EB,Abman SH,Adatia I,et al. Paediatric pulmonary arterial hypertension:updates on definition,classification,diagnostics and management[J]. Eur Respir J,2019,53(1):1801916.
[11] Lancaster TS,Shahanavaz S,Balzer DT,et al. Midterm outcomes of the Potts shunt for pediatric pulmonary hypertension,with comparison to lung transplant[J].J Thorac Cardiovasc Surg,2021,161(3):1139-1148.
[12] Ciarka A,Doan V,Velez-Roa S,et al. Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension[J]. Am J Respir Crit Care Med,2010,181(11):1269-1275.
[13] 黄华,张建卿,樊宗明,等. 肺动脉高压去交感神经术的研究进展[J]. 心肺血管病杂志,2023,42(4):383-385.
[14] Zhou L,Zhang J,Jiang XM,et al. Pulmonary artery denervation attenuates pulmonary arterial remodeling in dogs with pulmonary arterial hypertension induced
by dehydrogenized monocrotaline[J]. JACC Cardiovasc Interv,2015,8(15):2013-2023.
[15] Zhang H,Wei Y,Zhang C,et al. Pulmonary artery denervation for pulmonary arterial hypertension:a sham-controlled randomized PADN-CFDA trial[J]. JACC Cardiovasc Interv,2022,15(23):2412-2423.
[16] Hill C,Maxwell B,Boulate D,et al. Heart-lung vs. double-lung transplantation for idiopathic pulmonary arterial hypertension[J]. Clin Transplant,2015,29(12):1067-1075.
[17] Valapour M,Lehr CJ,Skeans MA,et al. OPTN/SRTR 2020 Annual
Data Report:Lung[J]. Am J Transplant,2022,22(suppl 2):438-518.
[18]de Perrot M,Granton JT,McRae K,et al. Outcome of patients with pulmonary arterial hypertension referred for lung transplantation:a 14-year single-center experience[J]. J Thorac Cardiovasc Surg,2012,143(4):910-918.
[19]Fadel E,Mercier O,Mussot S,et al. Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension:a comparative retrospective study of 219 patients[J]. Eur J Cardiothorac Surg,2010,38(3):277-284.
[20]Leard LE,Holm AM,Valapour M,et al. Consensus document for the selection of lung transplant candidates:an update from the International Society for Heart and Lung Transplantation[J]. J Heart Lung Transplant,2021,40(11):1349-1379.
[21]Weill D,Benden C,Corris PA,et al. A consensus document for the selection of lung transplant candidates:2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation[J]. J Heart Lung Transplant,2015,34(1):1-15.
[22] 王高峰,管丽华,周达新. 慢性血栓栓塞性肺动脉高压新治疗方法的进展[J]. 心血管病学进展,2022,43(1):14-17.
[23] 洪城,陈海明. 慢性血栓栓塞性肺动脉高压的介入治疗[J]. 中国临床新医学,2020,3(9):869-873.
[24] Nakamura M,Sunagawa O,Tsuchiya H,et al. Rescue balloon pulmonary angioplasty under veno-arterial extracorporeal membrane oxygenation in a patient with acute exacerbation of chronic thromboembolic pulmonary hypertension[J]. Int Heart J,2015,56(1):116-120.
[25] Wiedenroth CB,Liebetrau C,Breithecker A,et al. Combined pulmonary endarterectomy and balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension[J]．J Heart Lung Transplant,2016,35(5):591-596.
[26] Brenot P,Ja?s X,Taniguchi Y,et al. French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension[J]. Eur Respir J,2019,53:1802095.
[27] Ja?s X,Brenot P,Bouvaist H,et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension(RACE):a multicentre,phase 3,open-label,randomised controlled trial and ancillary follow-up study[J]. Lancet Respir Med,2022,10(10):961-971.
[28] 陶新曹,彭文华,谢万木,等. 球囊肺动脉成形术治疗慢性血栓栓塞性肺动脉高压的效果和安全性[J]. 中华医学杂志,2020,100(6):437-441.
[29] 吕朝阳,方堃,黄强,等. 肺动脉球囊扩张成形术治疗慢性血栓栓塞性肺动脉高压的安全性和有效性[J]. 中华放射学杂志,2020,54(1):48-52.
[30] 张智,毛敏,冷冰,等. 氧化应激与肺动脉高压关系研究进展[J]. 医学研究杂志，2013，42(2):17-20．
[31] Wang Y,Jing L,Zhao XM,et al. Protective effects of hydrogenrich saline on monocrotaline-induced pulmonary hypertension in a rat model[J]. Respir Res,2011,12(1):26.
[32] González-Saiz L,Fiuza-Luces C,Sanchis-Gomar F,et al. Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension:the WHOLEi+12 trial[J]. Int J Cardiol,2017,231:277-283.
[33] 冯晓岚,周旭,光雪峰,等. 干细胞移植治疗肺动脉高压研究进展[J]. 中国心血管病研究,2021,19(9):860-864.
[34] Rosenzweig EB,Chicotka S,Bacchetta M. Right ventricular assist device use in ventricular failure due to pulmonary arterial hypertension:lessons learned[J]. J Heart Lung Transplant,2016,35(10):1272-1274.
[35] Fuehner T,Kuehn C,Hadem J,et al. Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation[J]. Am J Respir Crit Care Med,2012,185(7):763-768.
[36] Olsson KM,Simon A,Strueber M,et al. Extracorporeal membrane oxygenation in nonintubated patients as bridge to lung transplantation[J]. Am J Transplant,2010,10(9):2173-2178.
[37]Lang G,Kim D,Aigner C,et al. Awake extracorporeal membrane oxygenation bridging for pulmonary retransplantation provides comparable results to elective retransplantation[J]. J Heart Lung Transplant,2014,33(12):1264-1272.

相似文献/References:

[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
　MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(1):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
　ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(1):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
　WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(1):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[4]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
　WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(1):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[5]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
　DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(1):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[6]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
　ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(1):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[7]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
　ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(1):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[8]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
　HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(1):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
[9]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
　LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(1):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[10]向杰 刘明鑫 张伟 黄从新.基于生物信息学分析探究肺动脉高压关键基因和通路[J].心血管病学进展,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
　Xiang JieLiu MingxinZhang WeiHuang Congxin.Bioinformatics Analysis of Key Genes and Pathways in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(1):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]

更新日期/Last Update: 2024-03-06